Company news
Agenus Inc. news in 2023
Agenus Inc.'s news releases, calls and decks from 2023, newest first.
Botensilimab/Balstilimab Data in Neoadjuvant Colorectal Cancer Selected for ASCO-GI 2024
December 19, 2023
Agenus to Receive $25 Million Milestone Payment from Bristol Myers Squibb for TIGIT-CD96 Bispecific Program
December 10, 2023
Agenus Reports Third Quarter 2023 Results
November 6, 2023
Agenus to Provide Third Quarter 2023 Financial Report and Corporate Update
October 25, 2023
Agenus Unveils New and Updated Botensilimab Data in Colorectal, Pancreatic, Lung, Melanoma, and Sarcoma
October 21, 2023
ESMO 2023: Agenus’ Botensilimab/Balstilimab Combination Delivers Durable Responses across Multiple Sarcoma Subtypes
October 20, 2023
Agenus Completes Enrollment in Randomized Phase 2 Clinical Trial of Botensilimab/Balstilimab in Advanced Colorectal Cancer
October 9, 2023
Agenus Prioritizes Resources to Accelerate Registration and Commercialization of BOT/BAL Program in Multiple Cancers
August 22, 2023
Agenus Reports Second Quarter 2023 Results
August 7, 2023
Agenus to Provide Second Quarter 2023 Financial Report and Corporate Update
July 25, 2023
Agenus Expands Executive Leadership Team
July 19, 2023
Agenus Provides Corporate Update and First Quarter 2023 Financial Results
May 8, 2023
Agenus Receives Fast Track Designation for Botensilimab and Balstilimab in Colorectal Cancer
April 16, 2023
Agenus Announces Dividend of 5 Million Shares of MiNK Therapeutics
March 29, 2023
Agenus Reports Fourth Quarter and Full Year 2022 Financial Results and Outlines 2023 Objectives
March 13, 2023
Calls in 2023
Decks in 2023
- Agenus Corporate Event at ESMO 2023
Conference · 34 slides · Oct 22, 2023